Tech-Based Health: Unlocking the World's 85% (The Global South)

The global health investment architecture rests on a structural miscalculation. For decades, Western venture capital and multinational healthcare conglomerates designed technology almost exclusively for the top 15% of humanity — the high-income G7 markets. That business model requires capital-intensive R&D and astronomical price points to deliver returns. Everyone else was written off as too low-margin, too fragmented, too risky.

That narrative is now obsolete.

A structural transformation is underway across Latin America. Regional science-based startups are redesigning diagnostic tools, point-of-care workflows, and health infrastructure specifically for low-resource, high-throughput environments. They capture massive, unpenetrated Total Addressable Markets that legacy multinationals cannot serve profitably. For institutional investors and development-oriented capital, this sector is now one of the most structurally underfunded high-margin asset classes in venture.

The Economic Thesis: A Systemic Care Gap

In emerging markets, market failure is not a lack of demand. It is a failure of legacy supply structures.

According to the Inter-American Development Bank, 55 million people in Latin America and the Caribbean — roughly 9.4% of the regional population — must travel at least 30 minutes to reach a health center (IDB, 2024). Out-of-pocket health expenditure remains punishingly high across the region: in Honduras, Grenada, and Guatemala, close to 50% of health spending falls directly on households (IDB, 2024).

This is a captive market desperate for decentralized, high-efficiency entry points. The Latin America medical devices market alone reached USD 29.3 billion in 2025, on track to US$55.1 billion by 2035 (Towards Healthcare, 2025). The regional point-of-care diagnostics segment is forecast to hit US$5.9 billion by 2030 at a 7.3% CAGR (Grand View Research, 2024).

Traditional multinationals cannot capture that demand because their cost structures are broken for this environment. A G7 diagnostic platform built around centralized labs, continuous refrigeration, specialized technicians, and high-margin consumables cannot operate profitably in a secondary city in Mexico, Colombia, or Brazil.

Regional "sciencepreneurs" are engineering the alternative. They apply miniaturized optical sensors, edge-computed AI diagnostic algorithms, low-bandwidth data synchronization, and ambient-temperature reagents. They deploy ruggedized, high-throughput biomedical engineering designed natively for global scale — not stripped-down versions of Western technology.

Why 'Tech-Based' Wins in Emerging Markets

Within the venture landscape, Tech-Based health assets sit at the intersection of risk, velocity, and capital efficiency.

Deep tech assets — novel drug discovery, gene therapy — require multiyear regulatory horizons and capital-intensive clinical trials. Tech-based solutions leverage proprietary, scalable software architectures integrated with hardware or operational workflows. They generate high-margin, repeatable B2B revenue with fast deployment. Global healthcare enterprise software alone reached US$30.8 billion in 2025, growing at 14.7% CAGR through 2033 (Grand View Research, 2025).

The Latin America and Caribbean deep tech ecosystem now includes 340 venture-backed startups with a combined ecosystem value of US$8 billion, healthcare among the top verticals (Dealroom / Hello Tomorrow, 2024). Deep tech captures 20% of global VC funding — up from 10% a decade ago (BCG, 2024).

Yet Latin American healthtech remains structurally underfunded. Healthcare represents 22% of global VC allocation, but healthtech captured only 3% of regional VC in 2024 — well below its macroeconomic weight (LAVCA, 2025). Argentina, Chile, and Uruguay together drive 89% of the region's biotech deals (LAVCA, 2025). Digital health in the region grew 37.6% in 2024 versus 5.5% globally (LAVCA, 2025). That mismatch is exactly the arbitrage window for institutional capital: entering high-margin B2B enterprise assets at reasonable entry valuations before late-stage global capital arrives.

Recent forensic analysis confirms the shift. The "State of LatAm Health Ecosystem 2025" report — coordinated by FrissOn Capital, FUMEC, and La Familia Foundation — found that 49.5% of the region's curated vanguard now operates within the Tech-Based bucket, and Infrastructure & Operations has consolidated as the top strategic pillar (254 companies, 25.22% of validated startups). This is a systemic pivot away from superficial direct-to-consumer apps and toward institutional B2B software and diagnostic foundations that solve margin compression for hospital networks and enterprise payers.

Investment Thesis Framework — Tech-Based Health Assets

Nearshoring 2.0: Mexico as the Manufacturing and Logistics Engine

The macro of 2026 introduces a critical tailwind. Nearshoring 1.0 was labor arbitrage. Nearshoring 2.0 is advanced technological assembly, biomedical supply chain resilience, and cross-border regulatory integration.

Mexico is the primary Access Gateway. Its medical device exports reached US$12.5 billion in 2023, making it the largest medical device exporter in Latin America and the eighth largest globally (Prodensa / Mexico industry data, 2024). The Baja California cluster alone concentrates over 50% of national medical device exports, with 75+ manufacturers and 74,000 workers (Tetakawi industry benchmark, 2025). Chihuahua adds another 30+ factories producing Class I-III devices with 40,000 workers.

The regulatory bridge is now real. Since September 2025, COFEPRIS has operated an Abbreviated Regulatory Pathway that approves devices in as few as 30 days when the manufacturer already holds FDA, Health Canada, or Japan Ministry of Health clearance (COFEPRIS, 2025). Combined with ISO 13485 equivalency to Mexico's NOM-241 standard, this eliminates the historic friction that slowed cross-border scale.

Manufacturing in Mexico costs roughly 25% less than in the US and 6% less than in China (Tetakawi industry benchmark, 2025). Applied biomedical diagnostics designed in Latin America can be assembled, precision-tested, and quality-controlled in Mexican industrial corridors, then shipped into North American supply chains on integrated ISO standards.

Dual-Jurisdiction Corporate Architecture

For institutional capital entering Latin America, operational execution must pair with legal defensibility. Historic friction has been cross-border tax inefficiency, regulatory fragmentation, and IP enforcement uncertainty.

The emerging institutional response is the Dual-Jurisdiction Corporate Architecture — commonly structured as a Canada Holdco Model. A neutral, well-regarded G7 holding entity houses IP and equity; the operating company executes on the ground.

This structure delivers three benefits. First, IP jurisdiction bridging — intellectual property generated by local sciencepreneurs is legally housed within a top-tier common-law jurisdiction, satisfying international acquirers. Second, tax treaty efficiency — Canada's bilateral network across Latin America and North America minimizes withholding on cross-border royalties, dividends, and liquidity events (Stratford Group / Welch LLP analysis, 2024). Third, governance standardization — investors participate in familiar common-law governance at the Holdco level, while operational teams run local OpCos with regional agility.

Compliance requirements are real. Intercompany royalties must reflect fair market value, and Base Erosion and Profit Shifting rules demand substance behind the IP structure. Properly executed, this architecture reduces cross-border execution risk to institutional-grade, turning emerging market biomedical innovation into a defensible asset class.

The Institutional Alignment: Returns Meet Impact

For development-oriented capital and impact-focused family offices, Tech-Based biomedical diagnostics in the Global South resolve the historic trade-off between financial return and measurable impact.

Capital deployed into applied diagnostic infrastructure delivers on three fronts. First, systemic health equity — unlocking early, accurate diagnostic screening for millions priced out by legacy G7 models. Second, economic productivity — shifting medicine from reactive emergency care to proactive, low-cost point-of-care detection. Third, institutional value creation — sustainable B2B enterprises with 5-10× MOIC potential over five to seven years, driven by high margins and strategic M&A exits.

The exit tailwind is now measurable. Cross-border M&A in Latin America is projected to grow 27.6% year-over-year in 2026, and healthtech M&A already rose 50% year-over-year 2024→2025 (industry aggregates, 2025). The Pharma Patent Cliff 2026-2032 will strip more than US$300 billion of legacy pharmaceutical revenue of exclusivity, driving strategic capital toward validated IP in emerging markets (PharmaVoice, 2025).

The Year of Proof

The PowerPoint Era of speculative digital health is over. We operate now in the Era of Proof. The structural challenges of the last two years battle-hardened a cohort of Latin American sciencepreneurs who have mastered the economics of serving the 85%.

Capital deployed into structurally underfunded Tech-Based assets — anchored by Mexico's Nearshoring 2.0 advantage and protected through Dual-Jurisdiction Corporate Architectures — is not a philanthropic bet. It is a high-conviction, capital-efficient strategy that positions institutional investors at the center of the next expansion of global healthcare.

The Global South is not waiting for Western technology to trickle down. It is engineering the future of sustainable, scalable, high-margin healthcare for the world.

Pedro López Sela is Managing Partner of FrissOn Capital, the Deep Tech Fund of Latin America. He is a bestselling author on innovation, business, and entrepreneurship.